BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 8523051)

  • 1. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
    Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
    J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
    Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
    J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
    Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
    J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
    Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
    J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel in patients with anthracycline-resistant advanced breast cancer.
    Vici P; Belli F; Di Lauro L; Amodio A; Conti F; Foggi P; Gionfra T; Morelli MF; Botti C; Ferraironi A; Lopez M
    Oncology; 2001; 60(1):60-5. PubMed ID: 11150910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
    Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
    J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients resistant to anthracycline therapy.
    Ravdin PM
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():13-6. PubMed ID: 8862704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
    J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
    Trudeau ME; Eisenhauer EA; Higgins BP; Letendre F; Lofters WS; Norris BD; Vandenberg TA; Delorme F; Muldal AM
    J Clin Oncol; 1996 Feb; 14(2):422-8. PubMed ID: 8636752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
    Ramos M; González-Ageitos A; Amenedo M; González-Quintas A; Gamazo JL; Togores P; Losada G; Almanza C; Romero C; Gómez-Martín C
    J Chemother; 2003 Apr; 15(2):192-7. PubMed ID: 12797398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
    J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
    Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
    J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
    Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
    Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
    Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
    Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
    Valero V
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-11-S13-18. PubMed ID: 9335512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance.
    Ando M; Watanabe T; Nagata K; Narabayashi M; Adachi I; Katsumata N
    J Clin Oncol; 2001 Jan; 19(2):336-42. PubMed ID: 11208824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel administered on a weekly basis for metastatic breast cancer.
    Burstein HJ; Manola J; Younger J; Parker LM; Bunnell CA; Scheib R; Matulonis UA; Garber JE; Clarke KD; Shulman LN; Winer EP
    J Clin Oncol; 2000 Mar; 18(6):1212-9. PubMed ID: 10715290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.